Cerus Corporation

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action enables INTERCEPT treatment to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, Russia, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development.
Company Growth (employees)
Type
Public
HQ
Concord, US
Size (employees)
204 (est)
Website
cerus.com
Cerus Corporation is headquartered in Concord, US

Key People at Cerus Corporation

William M. Greenman

William M. Greenman

President and CEO
Kevin D. Green

Kevin D. Green

VP, Finance & CFO
Laurence M. Corash

Laurence M. Corash

SVP, CMO & CSO

Cerus Corporation Office Locations

Cerus Corporation has offices in Concord and Amersfoort
Concord, US (HQ)
2550 Stanwell Dr
Amersfoort, NL
79 Stationsstraat

Cerus Corporation Data and Metrics

Cerus Corporation Financial Metrics

Cerus Corporation's revenue was reported to be $39.3 m in FY, 2016
USD

Net income (Q1, 2017)

(18.6 m)

EBIT (Q1, 2017)

(18.1 m)

Market capitalization (15-Sep-2017)

276.3 m

Cash (31-Mar-2017)

10.9 m
Cerus Corporation's current market capitalization is $276.3 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

39.7 m36.4 m34.2 m39.3 m

Revenue growth, %

(8%)(6%)15%

Cost of goods sold

22.6 m21.2 m23.5 m20.3 m

Gross profit

17.1 m15.2 m10.8 m19 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

8.6 m10.4 m7.7 m8.8 m8 m7.6 m9.3 m

Cost of goods sold

4.8 m5.7 m4.7 m7 m5.6 m4.3 m5 m

Gross profit

3.8 m4.7 m3 m1.8 m2.5 m3.4 m4.3 m

Gross profit Margin, %

45%45%39%20%31%44%46%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

29.5 m22.8 m71 m22.6 m

Accounts Receivable

6.1 m5.5 m5.8 m6.9 m

Inventories

13.1 m15 m10.8 m12.5 m

Current Assets

78.2 m74.9 m130.4 m94.1 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

28.6 m22.3 m17.9 m35.1 m50.8 m20.8 m7.7 m12.9 m10.9 m

Accounts Receivable

4.5 m7.4 m5.2 m5.4 m5.6 m4.1 m5.1 m7.4 m5.6 m

Inventories

13.4 m13.5 m16.1 m13.7 m12.8 m11.3 m12.1 m12.2 m12.9 m

Current Assets

70.3 m72.7 m136.4 m144.5 m128.4 m119.4 m112.2 m108 m75.7 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(43.3 m)(38.8 m)(55.9 m)(62.9 m)

Depreciation and Amortization

202 k202 k202 k202 m

Accounts Receivable

(1.7 m)632 k(301 k)(1.1 m)

Inventories

(1.8 m)3 m4 m(1.8 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(7.6 m)(10.8 m)(9.5 m)(16 m)(15.7 m)(16.9 m)(18.2 m)(14.4 m)(18.6 m)

Depreciation and Amortization

51 k50 k50 k51 k50 k50 k51 k50 k50 k

Accounts Receivable

4.5 m7.4 m5.2 m5.4 m5.6 m4.1 m5.1 m7.4 m5.6 m

Inventories

13.4 m13.5 m16.1 m13.7 m12.8 m11.3 m12.1 m12.2 m12.9 m
Y, 2017

Financial Leverage

2 x
Show all financial metrics

Cerus Corporation Operating Metrics

FY, 2016

Patents Issued

93
Show all operating metrics

Cerus Corporation Market Value History

Traffic Overview of Cerus Corporation

Cerus Corporation Company Life and Culture

You may also be interested in